Inclusion Criteria:  Age ≥18 years; Patient with neurofibromatosis type 1 according to NIH criteria ; Patient with a benign neurofibromatous lesion that is painful and/or generates functional discomfort and is unresectable or with unacceptable scarring ; Neutrophils > 1 G/l in the 14 days prior to inclusion; Adequate coagulation test (as judged by the investigator); Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment Covered by a medical insurance;  Exclusion Criteria:  Patient treated with concomitant chemotherapy and/or targeted therapies ; Any contraindication to a percutaneous cryotherapy procedure, including the need for ice formation within 1 cm of the spinal cord, brain or other critical nerve structures, bowel or bladder (unless active or passive thermal protective maneuvers are performed); Patient with malignant neurofibroma or MPNST ; NB: If tumor has progressed in the 12 months prior to inclusion: Prescription of a Pet scan and if SUV max T/F>1.5 targeted biopsy to confirm histology Patient with neurofibroma in areas at risk for neurological sequelae; Patient with cold urticaria with history of angioedema; Any cognitive impairment or condition that may limit the use of numerical scales and quality of life questionnaires; Patient for whom follow-up does not seem feasible even in the short term; Participation in another clinical trial that may interfere with the evaluation of the primary endpoint; Patient under tutorshio, curatorship or deprived of liberty; Pregnant or breast-feeding woman; Any contraindication to the performance of an MRI